Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human SIGLEC8/SAF-2 Antibody (1H10)

Catalog #:   DHK16102 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHK16102

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

SAF2, Sialoadhesin family member 2, SAF-2, Siglec-8, SIGLEC8, Sialic acid-binding Ig-like lectin 8

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NYZ4

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

1H10

Data Image
References

Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy., PMID:39725494

Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs., PMID:39474328

Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell Disorders., PMID:39456570

Increased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps., PMID:39253973

Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis., PMID:38666394

Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes., PMID:38217824

Regulation of mast cells by overlapping but distinct protein interactions of Siglec-6 and Siglec-8., PMID:38186079

Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells., PMID:37928558

Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases., PMID:37605867

Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial., PMID:37290787

Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas., PMID:37275334

Biomarkers for predicting type 2-high and uncontrolled asthma in real-world practice., PMID:37209833

Emerging therapies for eosinophilic esophagitis., PMID:36840634

Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy., PMID:36738782

Structures of the Inhibitory Receptor Siglec-8 in Complex with a High-Affinity Sialoside Analogue and a Therapeutic Antibody., PMID:36711084

Human Lung Mast Cells: Therapeutic Implications in Asthma., PMID:36430941

Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy., PMID:36248809

Pharmacological Induction of Granulocyte Cell Death as Therapeutic Strategy., PMID:36028226

Treatment Trends for Eosinophilic Esophagitis and the Other Eosinophilic Gastrointestinal Diseases: Systematic Review of Clinical Trials., PMID:35654734

Drug treatment strategies for eosinophilic esophagitis in adults., PMID:35379069

Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps., PMID:35253284

The Inhibitory Receptor Siglec-8 Interacts With FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation., PMID:35154156

Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro., PMID:34721399

Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases., PMID:34611316

Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab., PMID:34089846

Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge., PMID:33911007

Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody., PMID:33777047

Discovery, Function, and Therapeutic Targeting of Siglec-8., PMID:33374255

Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration., PMID:33289969

Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis., PMID:33085861

A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation., PMID:32814824

A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewisx., PMID:32744401

Divergent Siglec-F(eights) of mouse and human eosinophil death., PMID:32557797

An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells., PMID:32542913

Targeted Therapies for Eosinophilic Gastrointestinal Disorders., PMID:32472465

Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls., PMID:32134149

Clinical factors associated with acute exacerbations of chronic rhinosinusitis., PMID:32004523

Future therapies for eosinophilic gastrointestinal disorders., PMID:31778820

Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis., PMID:31465299

New treatments for chronic urticaria., PMID:31446134

AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice., PMID:31401630

Transcriptomics of atopy and atopic asthma in white blood cells from children and adolescents., PMID:30923181

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis., PMID:30886997

Therapeutic strategies for eosinophilic dermatoses., PMID:30743138

Mast Cell-Specific Expression of Human Siglec-8 in Conditional Knock-in Mice., PMID:30577572

Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies., PMID:30543818

Immunomodulators in chronic rhinosinusitis., PMID:30506050

New biologics in the treatment of urticaria., PMID:30015639

No difference in human mast cells derived from peanut allergic versus non-allergic subjects., PMID:29992767

Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro., PMID:29781747

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human SIGLEC8/SAF-2 Antibody (1H10) [DHK16102]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only